ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
Definitive 24 Gy radiotherapy for stage IE gastric MALT lymphoma: large-scale validation of an optimal dose with reduced acute toxicity.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDefinitive radiotherapy (RT) doses ≥ 30 Gy are traditionally applied for Helicobacter pylori-independent stage IE gastric mucosa-associated lymphoid tissue (MALT) lymphoma, achieving excellent control. Although 24 Gy may offer comparable efficacy with reduced toxicity, high-quality comparative data are limited. This study aimed to compare the efficacy, toxicity, and long-term outcomes of 24 and 30 Gy RT.
methodsWe retrospectively analyzed 202 patients treated with RT for stage IE gastric MALT lymphoma between 2009 and 2023 (24 Gy, n = 74; 30 Gy, n = 128) at a single tertiary institution. Outcomes included complete remission (CR), freedom from treatment failure (FFTF), overall survival (OS), and grade 2 acute toxicity. Statistical methods included Fisher’s exact test, logistic regression, and Kaplan–Meier estimation, with additional technique-adjusted subgroup analyses to account for temporal changes in RT practice.
resultsMedian follow-up was 55 months (24 Gy, 36 months; 30 Gy, 69 months; p < 0.001). All patients achieved CR, with 94.1% achieving within 6 months. The 5-year FFTF and OS rates were 99.4% and 100%, respectively. Grade 2 acute toxicity was significantly lower in the 24 Gy group (39.2%) than in the 30 Gy group (60.9%; p = 0.003). Nausea (39.6%) and dyspepsia (18.8%) were most common. Multivariable analysis identified higher-dose RT and female sex as independent predictors of toxicity. Only two patients (1.0%) experienced recurrence.
conclusionGiven its comparable disease control to 30 Gy and significantly lower acute toxicity, RT at 24 Gy should be considered the standard dose of choice in this setting.
Indexed as
Identifiers
41499054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.